Biotin (Cerenday) for permanent disability related to multiple sclerosis relapses – add on therapy to current immunomodulators
NIHR HSRIC
Record ID 32016000337
English
Authors' objectives:
Cerenday (biotin) is a high dose oral formulation of biotin, a water soluble vitamin that acts as a coenzyme for carboxylases involved in key steps of energy metabolism and fatty acid synthesis. Very high doses of biotin may be efficacious in multiple sclerosis (MS) by promoting myelin repair through activation of acetyl-CoA carboxylase, and by enhancing energy production in demyelinated neurons through activation of the tricarboxylic acid (Kreb's) cycle. Biotin is intended for use as an add-on therapy for permanent disability related to MS relapses, and is administered orally at 100mg three times daily for up to 24 months.
MS is a chronic immune-mediated condition of the central nervous system characterised by demyelination and axonal degeneration. Resultant damage leads to a wide spectrum of symptoms and signs, potentially including difficulties with weakness, sensory disturbance, balance and vision.
The prevalence of MS in England is approximately 0.16%, equivalent to approximately 85,600 affected people in England. Approximately 35.5% of patients have relapsing-remitting disease, equating to around 30,388 people in England. After two decades, more than half of patients who suffer from RRMS enter a secondary progressive phase.
Biotin is currently undergoing a phase III clinical trial assessing its effect on best corrected visual acuity compared with placebo. This trial is expected to complete by January 2016.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.hsric.nihr.ac.uk/topics/biotin-cerenday-for-permanent-disability-related-to-multiple-sclerosis-relapses-add-on-therapy-to-current-immunomodulators/
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Adjuvants, Immunologic
- Biotin
- Immunologic Factors
- Multiple Sclerosis
- Psychotherapy, Multiple
- Recurrence
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.